Droxinavir

Droxinavir (1 μM; 9 weekly passages) selects for resistant HIV-1 89-959 variants with the N88S protease mutation, which retain resistance to the compound for 9 weekly passages and exhibit an EC₅₀ of 580 nM; resistance persists after 26 passages without drug, with an EC₅₀ of 734 nM, and additional selection yields a variant with an EC₅₀ of 901 nM^[1].
Droxinavir (50 nM-16 μM; 21 weekly passages) selects for resistant HIV-1 LAI variants with L10F and N88S protease mutations, and these variants exhibit an EC₅₀ of 901 nM^[1].
Droxinavir has reduced efficacy against HIV-1 HXB2 clones with the N88S protease mutation alone or combined with L10F in MT2 cells, with EC₅₀ values of 46 nM and 61 nM, respectively^[1].
Droxinavir potently inhibits wild-type HIV-1 SF162 in PBMCs with an EC₅₀ of 11 nM, and SC-52151-selected HIV-1 SF162 variants retain susceptibility to the compound with an EC₅₀ of 4.0 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.